We’re excited to announce that today, Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site

Learn about accelerating target-to-lead antibody candidate selection with the Beacon platform in this Antibody Engineering & Therapeutics Digital Week 2019 webinar.

Please fill out the following form to access this resource:

First Name*
Last Name*
Email Address*
Phone Number*
City*
Country*
State*
Company/Institute*
CAPTCHA

Related Resources

View All Resources

Antibody Discovery Cell Line Development

Customer Spotlight: Amgen on the Berkeley Lights Platform

Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.

Antibody Discovery

Poster: Plasma B Cell Cloning

Berkeley Lights and ChemPartner provide a case study in accelerated discovery of unique Anti-PD-L1 antibodies from spleen versus bone marrow of immunized mice, via single plasma B cell cloning on the Beacon platform.

Antibody Discovery

Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow

Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.